Wall Street Zen Upgrades Inhibikase Therapeutics (NASDAQ:IKT) to Sell

Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by Wall Street Zen to a “sell” rating in a report issued on Saturday.

Several other brokerages also recently weighed in on IKT. Lifesci Capital upgraded Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Finally, Cantor Fitzgerald upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Thursday, December 11th. Three equities research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Inhibikase Therapeutics presently has an average rating of “Buy”.

Inhibikase Therapeutics Stock Performance

IKT stock opened at $2.00 on Friday. The stock has a market cap of $150.36 million, a PE ratio of -5.13 and a beta of 0.88. Inhibikase Therapeutics has a 12 month low of $1.33 and a 12 month high of $3.49. The business’s 50-day moving average price is $1.56.

Inhibikase Therapeutics (NASDAQ:IKT) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.